Navigation Links
Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
Date:10/17/2007

Takeda Will Continue to Dominate the Type 2 Diabetes Market, According to a

New Report from Decision Resources

WALTHAM, Mass., Oct. 17 /PRNewswire/ -- Decision Resources and Millennium Research Group have released a new report finding that Merck will obtain blockbuster antidiabetic drug sales in the type 2 diabetes market by 2011, thanks to uptake of their DPP-IV inhibitor, Januvia. Januvia will see rapid uptake as a second-and third-line agent in type 2 diabetes treatment and its success will propel Merck into the diabetes market, giving the company 15 percent of the market in 2011. Januvia will become the second-leading blockbuster in the market, behind only Takeda's Actos. Surveyed primary care physicians ranked Merck as best for product innovation.

"The choice of Merck as 'best' for product innovation in type 2 diabetes indicates physicians' enthusiasm for Januvia," said Elena Rossi, analyst at Millennium Research Group. "This enthusiasm is echoed by the 71 percent of surveyed physicians who believe that Merck will be one of the most influential companies in type 2 diabetes over the next five years."

The report also finds that Takeda led the type 2 diabetes drug market in 2006 with a market share of almost 30 percent from sales of the PPAR-gamma agonist Actos; however, this share will fall to about 21 percent in 2011 due to strong competition from the novel DPP-IV inhibitors (like Januvia) and GLP- 1 analogues (such as Eli Lilly/Amylin's Byetta). Nonetheless, the Actos franchise will continue to gain uptake in the market due in part to the launch of a novel fixed-dose combination of Actos with extended-release metformin. Furthermore, Takeda is developing a novel DPP-IV inhibitor, algoliptin, that is expected to launch in the United States and Europe in 2009 and provide strong competition for Januvia.

About Brands & Strategies

Brands & Strategies is the first and only report series to bring together all of the competitive information elements biopharmaceutical companies need to make informed decisions about their products and the best next-steps. Each report includes the following:

-- Physician perceptions of companies and brand attributes

-- Physician preference for sources of information

-- Physician opinion of future strategies, messaging, and upcoming events

-- Overview of competitive landscape

-- Pipeline analysis by company within a specific disease

-- SWOT analysis on each brand

-- Brand lifecycle strategy, including clinical trial competitive analysis

-- Trend analysis of brand-specific messaging

-- Brand-specific, event-driven, five-year annualized market forecast

-- Country-specific, event-driven market share projections by company and

brand

-- Drug class and brand vs. generics sales by country

-- Pricing analysis with company-specific strategy, price for all drugs

over five years, impact of generics

-- Analysis of promotional spend for each product

-- Selling strategies based on clinical trials

-- Prevalent and diagnosed population by country

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), part of the Decision Resources, Inc., family, is a leading provider of strategic information to the healthcare sector. Focused on the medical device, pharmaceutical, and biotechnology industries, the company provides clients its specialized industry expertise through published reports and customized consulting services.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Quality assurance of RNA derived from laser microdissected tissue samples obtained by the PALM MicroBeam System using the RNA 6000 Pico LabChip kit.
2. High Electrotransformation Efficiencies Obtained With DNA From Ligation Mixtures
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Though pharma growth slides, blockbusters reach new record
5. Jellyfish partners for sales tracking technology
6. Doyle wants sales tax applied to digital downloads
7. Mortgagebot builds online sales even as housing declines
8. Third Wave reports another loss, stronger sales
9. Johnson Controls reports record quarterly sales
10. Can sales outsourcing grow Wisconsin biotechs?
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... on a range of subjects including policies, debt and investment ... Speaking at a lecture to the Canadian Economics ... the country,s inflation target, which is set by both the ... "In certain areas there needs to be frequent ... not sit down and address strategy together?" He ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
Breaking Biology Technology:
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):